-
Cancer Treatment Reports Jun 1985
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Colonic Neoplasms; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia
PubMed: 4016775
DOI: No ID Found -
Cancer Treatment Reports 1984
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Drug Evaluation; Humans; Kidney Neoplasms; Middle Aged
PubMed: 6744342
DOI: No ID Found -
Cancer Treatment Reports Sep 1984
Topics: Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Drug Evaluation; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged
PubMed: 6478455
DOI: No ID Found -
Cancer Treatment Reports 1985
Topics: Adult; Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Carcinoma, Bronchogenic; Drug Evaluation; Humans; Lung Neoplasms; Middle Aged
PubMed: 4016800
DOI: No ID Found -
Cancer Treatment Reports Feb 1985Seventeen patients with metastatic colon cancer received diaziquone iv daily for 5 days repeated every 28 days. Based on recommended starting doses for phase II trials... (Clinical Trial)
Clinical Trial
Seventeen patients with metastatic colon cancer received diaziquone iv daily for 5 days repeated every 28 days. Based on recommended starting doses for phase II trials (6-8 mg/m2 daily X 5), the first six patients received 7 mg/m2/day X 5. Two of these patients were heavily pretreated with chemotherapy, two had received prior 5-FU alone, and two had received no prior chemotherapy. There were no responses and three septic deaths (both of the heavily pretreated patients and one 5-FU-only patient who received concurrent radiotherapy). Eleven subsequent patients received 5.5 mg/m2/day X 5. Nine had no prior therapy; two had received prior 5-FU. No antitumor responses were observed. Myelosuppression was again the major toxic effect. No further septic deaths occurred. Diaziquone in this dose and schedule had no antitumor activity in this group of patients.
Topics: Adult; Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Male; Middle Aged
PubMed: 3882229
DOI: No ID Found -
Cancer Treatment Reports Sep 1985
Topics: Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Bone Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Sarcoma; Soft Tissue Neoplasms
PubMed: 4028037
DOI: No ID Found -
Cancer Treatment Reports Nov 1987
Topics: Adult; Aged; Aziridines; Azirines; Benzoquinones; Diagnosis-Related Groups; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma
PubMed: 3119202
DOI: No ID Found -
Biophysical Chemistry Jun 1985The one-electron electrochemical reduction of diaziquone (AZQ) and 12 analogs is analyzed using ESR spectroscopy and cyclic voltammetry. The hyperfine coupling constants... (Comparative Study)
Comparative Study
The one-electron electrochemical reduction of diaziquone (AZQ) and 12 analogs is analyzed using ESR spectroscopy and cyclic voltammetry. The hyperfine coupling constants arising from the interaction of the unpaired electron with the aziridine nitrogen nuclei fall within 1.20 and 2.26 G. Smaller couplings are observed arising from the protons and nitrogens in the carboethoxyamino groups. The in vitro activity of AZQ and its analogs is examined. Methyl groups in the aziridine rings increase the activity of some analogs. In the absence of aziridines, a chloroquinone compound with only carboethoxyamino groups was surprisingly active. This compound has a more positive cathodic peak than diaziquone.
Topics: Animals; Aziridines; Azirines; Benzoquinones; Cell Division; Electrochemistry; Electron Spin Resonance Spectroscopy; Free Radicals; Leukemia L1210; Mice; Structure-Activity Relationship
PubMed: 2992620
DOI: 10.1016/0301-4622(85)80032-6 -
Biochemical Pharmacology May 1985Human leukemic cell lines K562 and HL60, and the murine leukemic cell line L1210, reduce Diaziquone (AZQ) (NCS182986) to its free radical anion. With all cell lines, the...
Human leukemic cell lines K562 and HL60, and the murine leukemic cell line L1210, reduce Diaziquone (AZQ) (NCS182986) to its free radical anion. With all cell lines, the free radical was observed immediately in both aerobic and anaerobic cell suspensions. The steady-state concentration of AZQ free radicals was approximately 1% of the total AZQ concentration. L1210 cells treated with azide reduced AZQ, but cells treated with diamide and N-ethylmaleimide did not. NADPH and L-cysteine reduced AZQ. The latter did so under anaerobic conditions; the former did so under both anaerobic and aerobic conditions.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Cell Line; Ethylmaleimide; Free Radicals; Humans; Kinetics; Leukemia; Leukemia L1210; Mice; NADP; Oxygen Consumption
PubMed: 3994758
DOI: 10.1016/0006-2952(85)90683-5 -
Oncology (Williston Park, N.Y.) Aug 1989Managing patients with relapsed acute myeloid leukemia is a major clinical challenge. Although 60-70% of patients with AML achieve complete remission following induction... (Review)
Review
Managing patients with relapsed acute myeloid leukemia is a major clinical challenge. Although 60-70% of patients with AML achieve complete remission following induction therapy with cytarabine and an anthracycline, at least 70-80% of patients achieving remission eventually relapse. While there are few comparative trials that provide therapeutic guidelines, an initial decision as to treatment can be seen as a choice between reusing previously effective drugs or initiating new classes of drugs. Some of the newer agents which have definite activity include amsacrine, mitoxantrone, diaziquone, idarubicin, homoharringtonine, and carboplatin. Allogeneic, autologous, and syngeneic bone marrow transplantation probably represent the preferred approaches in suitable patients, either in early relapse or after second remission is achieved.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Myeloid; Neoplasm Recurrence, Local
PubMed: 2519195
DOI: No ID Found